BPC-157 and Ligament Healing: The Evidence
BPC-157
90 days tracked
The only direct ligament study tracked BPC-157-treated MCL healing for 90 days, showing consistent functional, biomechanical, and histological improvement across three administration routes.
Cerovecki et al., J Orthop Res, 2010
Cerovecki et al., J Orthop Res, 2010
View as imageLigament injuries are among the most common musculoskeletal problems in sports medicine, and they heal slowly because ligaments have limited blood supply. BPC-157, a 15-amino-acid peptide originally isolated from human gastric juice, has been tested across multiple connective tissue injury models in rats, including one dedicated ligament study. That single ligament study, published in the Journal of Orthopaedic Research in 2010, remains the only published investigation of BPC-157's direct effects on ligament healing. The rest of what we know about BPC-157 and connective tissue comes from tendon studies that share relevant biology with ligaments, and from mechanistic work on fibroblasts, the cells responsible for producing collagen in both tissues. This article covers all of it: the single ligament study, the supporting tendon evidence, the proposed mechanisms, and what remains unknown.
Key Takeaways
- The Cerovecki 2010 study is the only published investigation of BPC-157 on ligament healing, showing improved MCL repair across functional, biomechanical, macroscopic, and histological endpoints in rats over 90 days.[1]
- BPC-157 was effective via three administration routes: intraperitoneal (10 micrograms or 10 ng/kg), oral (0.16 micrograms/ml in drinking water), and topical cream applied directly to the injury site.[1]
- In tendon studies, BPC-157 promoted tendon outgrowth, cell survival, and cell migration through FAK-paxillin signaling and MAPK/ERK pathway activation.[5]
- BPC-157 dose- and time-dependently increased growth hormone receptor expression in tendon fibroblasts at both mRNA and protein levels, potentially amplifying the anabolic healing response.[6]
- BPC-157 modulated angiogenesis in healing tissue without direct angiogenic effects on cell cultures, suggesting it works through indirect vascular recruitment rather than direct blood vessel stimulation.[7]
- A 2025 systematic review of BPC-157 in orthopaedic sports medicine found only 1 clinical study assessing musculoskeletal outcomes out of 544 articles identified.[10]
The Cerovecki 2010 study: the only ligament evidence
There is exactly one published study that tested BPC-157 on ligament healing. Cerovecki et al. (2010) surgically transected the medial collateral ligament (MCL) of rats and tracked healing for 90 days across multiple treatment groups.[1]
The MCL was chosen because it is one of the most commonly injured knee ligaments in humans and has a well-characterized healing response in rats. After surgical transection, animals received BPC-157 through one of three routes:
- Intraperitoneal injection: 10 micrograms or 10 ng/kg, once daily
- Oral: 0.16 micrograms/ml dissolved in drinking water (approximately 12 ml/day/rat)
- Topical: 1.0 microgram dissolved in distilled water per gram of neutral cream, applied as a thin layer to the injury site, starting 30 minutes after surgery
The researchers measured four categories of healing outcomes:
Functional improvement. BPC-157-treated rats showed better functional use of the injured limb compared to controls across the 90-day observation period.
Biomechanical strength. The healed ligaments in BPC-157 groups demonstrated improved mechanical properties. While the study did not report specific percentage increases in the abstract, it characterized the improvements as "consistent" across multiple biomechanical parameters.
Macroscopic appearance. On gross examination, BPC-157-treated MCLs showed better tissue organization and more advanced healing compared to controls at each time point assessed.
Histological quality. Microscopic examination revealed faster and better-organized connective tissue formation in BPC-157-treated animals. The healing tissue showed more advanced collagen fiber organization and vascular development compared to untreated controls.[1]
The fact that all three routes of administration produced consistent improvements is one of the most relevant findings. Intraperitoneal injection delivers BPC-157 systemically, bypassing the gastrointestinal tract. Oral administration tests whether the peptide survives gastric digestion and reaches the injury site through the bloodstream. Topical application tests whether direct contact with the healing tissue is sufficient. That BPC-157 worked through all three suggests multiple potential pathways to the injury site, which has implications for any future clinical application.
This study built on the same group's earlier tendon work, which had already demonstrated that BPC-157 enhanced healing of transected Achilles tendon with expression of the early growth response 1 (egr-1) gene, a transcription factor involved in collagen production, cell proliferation, and tissue remodeling.[1]
Supporting evidence from tendon studies
Ligaments and tendons are both dense connective tissues composed primarily of type I collagen, produced by fibroblasts. They differ in function (ligaments connect bone to bone; tendons connect muscle to bone) and in their cellular environment, but the healing biology overlaps substantially. The tendon evidence for BPC-157 is therefore directly relevant to understanding its potential ligament effects.
Achilles tendon transection (Staresinic 2003)
The foundational tendon study was published by Staresinic et al. in 2003. After surgically transecting the Achilles tendon in rats, BPC-157 improved healing across four measurement categories: biomechanical (increased load to failure, load to failure per area, and Young's modulus of elasticity), functional (higher Achilles functional index values), microscopic (more mononuclear cells and fewer granulocytes, superior formation of fibroblasts, reticulin, and collagen), and macroscopic (smaller and shallower tendon defects with faster restoration of full tendon integrity).[2]
The in vitro component of this study showed that BPC-157 directly stimulated tendocyte growth in cell culture, establishing that the peptide has direct effects on the connective tissue cells themselves, not just indirect effects through improved blood supply or reduced inflammation.[2]
Tendon-to-bone healing (Krivic 2006, 2008)
Krivic et al. conducted two studies on Achilles tendon detachment from bone, a model that tests healing at the enthesis (the junction where tendon or ligament inserts into bone). This junction is particularly relevant to ligament injuries because many clinically important ligament injuries, including ACL tears, involve damage at or near the bone insertion.
In the 2006 study, BPC-157 promoted tendon-to-bone healing and opposed the healing impairment caused by corticosteroid treatment. BPC-157 improved functional recovery, increased biomechanical strength (load to failure, stiffness, and Young's modulus), and produced better-organized collagen fibers with more advanced vascular appearance on microscopy. Corticosteroids, commonly used for post-injury inflammation, worsened all healing parameters, and BPC-157 counteracted this aggravation.[3]
The 2008 follow-up focused on early functional recovery, comparing BPC-157 to methylprednisolone. BPC-157-treated rats showed earlier return of function after tendon-to-bone transection, while methylprednisolone delayed functional recovery. This temporal advantage is relevant because early functional recovery correlates with long-term healing quality in connective tissue injuries.[4]
The corticosteroid opposition findings are relevant to ligament injury management because corticosteroid injections are sometimes used for ligament-related pain and inflammation. If BPC-157's ligament effects translate to larger animal models or humans, the finding that it counteracts corticosteroid-induced healing impairment would have practical clinical value.
Proposed mechanisms of action
Three research groups have investigated how BPC-157 promotes connective tissue healing at the cellular and molecular level. The mechanistic evidence comes from tendon fibroblast studies, but the pathways identified are active in ligament fibroblasts as well.
FAK-paxillin signaling and cell migration (Chang 2011)
Chang et al. (2011) used in vitro Achilles tendon models to demonstrate that BPC-157 promotes tendon healing through three specific cellular processes: tendon outgrowth from the cut end, cell survival under stress conditions, and cell migration toward the injury site. The molecular pathway involved activation of focal adhesion kinase (FAK) and its downstream target paxillin, which together regulate how cells attach to and move through the extracellular matrix.[5]
BPC-157 also activated the MAPK/ERK pathway, upregulating phosphorylation of ERK1/2 and their downstream transcription factor targets including c-Fos, c-Jun, and EGR-1. These molecules are involved in cell growth, migration, and the angiogenic response. This signaling cascade provides a molecular explanation for the consistent healing improvements observed across different connective tissue types.[5]
Growth hormone receptor upregulation (Chang 2014)
Chang et al. (2014) used cDNA microarray analysis to identify which genes BPC-157 affects in tendon fibroblasts. The growth hormone receptor (GHR) emerged as one of the most abundantly upregulated genes. Follow-up experiments confirmed that BPC-157 dose- and time-dependently increased GHR expression at both the mRNA and protein levels.[6]
Growth hormone signaling through its receptor is a major driver of tissue repair and collagen synthesis. By increasing the density of GH receptors on fibroblasts, BPC-157 may amplify the cells' responsiveness to circulating growth hormone, effectively boosting the anabolic healing signal without increasing GH levels themselves. This is a distinct mechanism from growth hormone secretagogues, which increase GH production. BPC-157 appears to make cells more receptive to the GH already present.[6]
Angiogenesis modulation (Brcic 2009)
Brcic et al. (2009) investigated the relationship between BPC-157 and angiogenesis (new blood vessel formation) in muscle and tendon healing using both in vitro and in vivo models. The results revealed a paradox: BPC-157 had no direct angiogenic effect on cell cultures, yet immunohistochemical analysis of healing muscle and tendon tissue showed modulated angiogenesis in BPC-157-treated animals, as measured by VEGF, CD34, and Factor VIII antibody staining.[7]
This distinction is important. BPC-157 does not directly stimulate blood vessel growth the way VEGF does. Instead, it appears to modulate the angiogenic response in the context of tissue injury, potentially by recruiting existing vascular pathways rather than creating new ones from scratch. For ligament healing, where poor blood supply is the primary barrier to recovery, even indirect improvement in vascular support could accelerate repair.
Seiwerth et al. (2018) expanded this framework, comparing BPC-157's effects with standard angiogenic growth factors across gastrointestinal, tendon, ligament, muscle, and bone healing. They argued that BPC-157 activates the same downstream healing pathways as growth factors like VEGF and FGF, but through an upstream mechanism that is not yet fully characterized. Unlike recombinant growth factors, which are expensive and require carriers for delivery, BPC-157 is a small, stable peptide that works without a carrier matrix.[8]
Reviews and systematic evidence
Two independent reviews have assessed BPC-157's musculoskeletal evidence.
Gwyer et al. (2019) published a critical review in Cell and Tissue Research examining BPC-157 as a potential therapy for musculoskeletal soft tissue damage. They noted that "all studies investigating BPC 157 have demonstrated consistently positive and prompt healing effects for various injury types, both traumatic and systemic." However, they also highlighted that the evidence is entirely preclinical and that the mechanism of action remains incompletely understood, with most data pointing to EGR-1 upregulation and angiogenic modulation as key pathways.[9]
Vasireddi et al. (2025) conducted a systematic review of BPC-157 in orthopaedic sports medicine, published in the HSS Journal. Of 544 articles initially identified, only 36 met inclusion criteria for the review, and only 1 clinical study assessed musculoskeletal outcomes. The vast disparity between published preclinical work and clinical evidence underscores the translational gap. The preclinical data is consistently positive, but it has not been tested in controlled human trials for any musculoskeletal indication.[10]
Limitations specific to ligament evidence
The ligament evidence for BPC-157 has several limitations beyond those shared with all BPC-157 research.
Single study, single model. The entire ligament evidence rests on one study (Cerovecki 2010) using one ligament (MCL) in one species (rat). The MCL is an extra-articular ligament with a blood supply and healing capacity that differs from intra-articular ligaments like the ACL, which has poor intrinsic healing ability in humans. BPC-157's effects on MCL healing may not predict effects on ACL, PCL, or other ligaments with different vascular environments.
No dose-response data for ligament. The Cerovecki study tested only two doses for the intraperitoneal route. Unlike the gastric ulcer evidence, where Xue et al. (2004) tested three doses across three models, there is no ligament-specific dose-response curve to identify optimal dosing.
Extrapolation from tendon data. Much of the mechanistic understanding comes from tendon studies. While tendons and ligaments share type I collagen composition and fibroblast-driven healing, they differ in loading patterns, cellular density, and vascular supply. Assuming identical responses is not justified without direct testing.
No comparison to established therapies. The Cerovecki study compared BPC-157 to untreated controls but not to any established ligament healing intervention. In clinical orthopedics, platelet-rich plasma (PRP), physical therapy protocols, and surgical reconstruction are standard approaches. Without head-to-head comparisons, BPC-157's relative effectiveness against existing treatments is unknown.
Zagreb group concentration. The Cerovecki study came from the same University of Zagreb group that has produced the majority of BPC-157 research. Independent replication from other institutions is limited, though Chang et al.'s Taiwanese fibroblast studies provide some independent mechanistic support.[5][6]
Species translation. Rat MCL dimensions, loading conditions, and healing timelines differ from human ligaments. The 90-day rat timeline cannot be directly mapped to human recovery. The broader question of translating BPC-157 animal data to human outcomes applies to every preclinical finding in this article.
The Bottom Line
BPC-157 has one dedicated ligament study showing improved MCL healing in rats across functional, biomechanical, and histological measures over 90 days, supported by multiple tendon studies demonstrating similar connective tissue repair through FAK-paxillin signaling, growth hormone receptor upregulation, and angiogenesis modulation. The mechanistic evidence is plausible, but the translational gap is wide: no controlled human trial has tested BPC-157 for any ligament injury, and the single ligament study used an extra-articular ligament model that may not predict effects on intra-articular ligaments like the ACL.